Search results for "AMYOTROPHIC LATERAL SCLEROSIS"

showing 10 items of 228 documents

Oxidative Stress, Neuroinflammation and Mitochondria in the Pathophysiology of Amyotrophic Lateral Sclerosis

2020

Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron (MN) disease. Its primary cause remains elusive, although a combination of different causal factors cannot be ruled out. There is no cure, and prognosis is poor. Most patients with ALS die due to disease-related complications, such as respiratory failure, within three years of diagnosis. While the underlying mechanisms are unclear, different cell types (microglia, astrocytes, macrophages and T cell subsets) appear to play key roles in the pathophysiology of the disease. Neuroinflammation and oxidative stress pave the way leading to neurodegeneration and MN death. ALS-associated mitochondrial dysfunction occurs at different le…

0301 basic medicineamyotrophic lateral sclerosisPhysiologyClinical BiochemistryReviewDiseaseMitochondrionmedicine.disease_causeBiochemistryneuroinflammationNeurologia03 medical and health sciences0302 clinical medicineoxidative stressMedicineAmyotrophic lateral sclerosisMolecular BiologyNeuroinflammationMicrogliabusiness.industrylcsh:RM1-950NeurodegenerationCell Biologymedicine.diseasePatologiaPathophysiologymitochondrialcsh:Therapeutics. Pharmacology030104 developmental biologymedicine.anatomical_structuremotor neuron diseasebusinessNeuroscience030217 neurology & neurosurgeryOxidative stressAntioxidants
researchProduct

Functions and Therapeutic Potential of Extracellular Hsp60, Hsp70, and Hsp90 in Neuroinflammatory Disorders

2021

Neuroinflammation is implicated in central nervous system (CNS) diseases, but the molecular mechanisms involved are poorly understood. Progress may be accelerated by developing a comprehensive view of the pathogenesis of CNS disorders, including the immune and the chaperone systems (IS and CS). The latter consists of the molecular chaperones; cochaperones; and chaperone cofactors, interactors, and receptors of an organism and its main collaborators in maintaining protein homeostasis (canonical function) are the ubiquitin–proteasome system and chaperone-mediated autophagy. The CS has also noncanonical functions, for instance, modulation of the IS with induction of proinflammatory cytokines. …

0301 basic medicineamyotrophic lateral sclerosislcsh:TechnologychaperonopathiesProinflammatory cytokinelcsh:Chemistrys disease03 medical and health sciences0302 clinical medicinechaperone systemmedicineamyotrophic lateral sclerosiGeneral Materials Sciencelcsh:QH301-705.5InstrumentationchaperonotherapyNeuroinflammationFluid Flow and Transfer Processesbiologylcsh:TMechanism (biology)Process Chemistry and Technologymolecular chaperonesNeurodegenerationAutophagyGeneral EngineeringParkinson’S diseasemolecular chaperonemedicine.diseaseHuntington’ s diseaseHsp90lcsh:QC1-999Computer Science Applications030104 developmental biologylcsh:Biology (General)lcsh:QD1-999lcsh:TA1-2040multiple sclerosiChaperone (protein)Alzheimerbiology.proteinHSP60lcsh:Engineering (General). Civil engineering (General)Alzheimer’s diseaseNeurosciencelcsh:Physics030217 neurology & neurosurgeryHuntington’s diseaseApplied Sciences
researchProduct

Therapeutic alternative of the ketogenic Mediterranean diet to improve mitochondrial activity in Amyotrophic Lateral Sclerosis (ALS): A Comprehensive…

2019

Abstract Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease which is pathogenically based on the mitochondrial alteration of motor neurons, causing progressive neuron death. While ALS is characterized by enormous oxidative stress, the Mediterranean diet has been seen to have high antioxidant power. Therefore, the aim of this study is to determine how the Mediterranean diet can improve mitochondrial activity, establishing the specific nutrients and, in addition, observing the pathogenic mechanisms related to the disease that would achieve this improvement. To this end, a comprehensive review of the literature was performed using PubMed. KBs have been observed to ha…

0301 basic medicineamyotrophic lateral sclerosismitochondria ; mediterranean diet ; amyotrophic lateral sclerosis ; ketone bodiesMediterranean dietReviewslcsh:TX341-641ReviewDiseaseMitochondrionBioinformaticsmedicine.disease_causeNeuroprotection03 medical and health sciences0302 clinical medicineKetogenesisMedicineAmyotrophic lateral sclerosisbusiness.industryfood and beveragesmediterranean dietmedicine.diseasemitochondria030104 developmental biologyketone bodiesbusinessNeuron deathlcsh:Nutrition. Foods and food supply030217 neurology & neurosurgeryOxidative stressFood ScienceFood Science & Nutrition
researchProduct

Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review

2020

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that produces a selective loss of the motor neurons of the spinal cord, brain stem and motor cortex. Oxidative stress (OS) associated with mitochondrial dysfunction and the deterioration of the electron transport chain has been shown to be a factor that contributes to neurodegeneration and plays a potential role in the pathogenesis of ALS. The regions of the central nervous system affected have high levels of reactive oxygen species (ROS) and reduced antioxidant defences. Scientific studies propose treatment with antioxidants to combat the characteristic OS and the regeneration of nicotinamide adenine dinucleotide (NAD+) lev…

0301 basic medicineamyotrophic lateral sclerosispterostilbenePterostilbenePhysiologyCentral nervous systemReviewPharmacologyNicotinamide adenine dinucleotidemedicine.disease_causelcsh:Physiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)mitochondrial dysfunctionmedicineoxidative stressneurodegenerative diseasesAmyotrophic lateral sclerosisnicotinamide ribosidelcsh:QP1-981business.industryNeurodegenerationmedicine.disease030104 developmental biologymedicine.anatomical_structurechemistryNicotinamide ribosideNAD+ kinasebusiness030217 neurology & neurosurgeryOxidative stressFrontiers in Physiology
researchProduct

Neurotrophic and neuroprotective effects of muscle contraction

2016

Background: Physical activity has been shown to be associated with reduced risk of coronary heart disease but the same effect seems to be produced in neurological diseases. Objective: In this review, we focused on the interplay between physical activity and some neurological conditions (Stroke, dementia, epilepsy, headache, Parkinson’ s disease, amyotrophic lateral sclerosis, multiple sclerosis, insomnia, depression and anxiety) with the aim of describing the potential role of physical activity in the prevention of such diseases and the physiological mechanisms involved in these processes. Results: Despite a growing body of evidence which reveals that physical activity is able to reduce the…

0301 basic medicinemedicine.medical_specialtyDiseaseBioinformaticsNeuroprotection03 medical and health sciencesEpilepsyPhysical medicine and rehabilitationDrug DiscoverymedicineHumansDementiaNervous System Physiological PhenomenaAmyotrophic lateral sclerosisStrokeExerciseLife StyleNervous System DiseaseDepression (differential diagnoses)EndocannabinoidPharmacologybusiness.industryPhysical activityMultiple sclerosisPreventionBrain-Derived Neurotrophic FactorRehabilitationOxidative Stremedicine.diseaseLifestyleStrokeOxidative Stress030104 developmental biologyCerebrovascular CirculationDementiaNervous System DiseasesbusinessNeurological diseaseEndocannabinoidsHumanMuscle Contraction
researchProduct

Neurological aspects of medical use of cannabidiol

2017

Background: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential therapeutic properties, including neuroprotective effects in numerous pathological conditions. CBD neuroprotection is due to its antioxidant and antiinflammatory activities and the modulation of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases. Objective: The aim of the present review was to describe the state of art about the pre-clinical research, the potential use and, when existing, t…

0301 basic medicinemedicine.medical_specialtyNeurologyCannabidiol; Neurodegenerative diseases; Neurological; Neurology; Neuroprotection; Neuroscience (all); PharmacologyDiseaseBioinformaticsNeurodegenerative diseaseNeuroprotection03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegaleCentral Nervous System DiseasesMedicineAnimalsCannabidiolHumansneurodegenerative diseasesYoung adultAmyotrophic lateral sclerosisPharmacologyNeuroscience (all)biologybusiness.industryGeneral NeuroscienceMultiple sclerosismedicine.diseasebiology.organism_classificationNeuroprotection030104 developmental biologyNeuroprotective AgentsNeurologyNeurologicalcannabidiol; neurodegenerative diseases; neurological; neurology; neuroprotectionCannabisbusinessCannabidiol030217 neurology & neurosurgerymedicine.drug
researchProduct

Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS

2010

Summary Using exome sequencing, we identified a p.R191Q amino acid change in the valosin-containing protein ( VCP ) gene in an Italian family with autosomal dominantly inherited amyotrophic lateral sclerosis (ALS). Mutations in VCP have previously been identified in families with Inclusion Body Myopathy, Paget disease, and Frontotemporal Dementia (IBMPFD). Screening of VCP in a cohort of 210 familial ALS cases and 78 autopsy-proven ALS cases identified four additional mutations including a p.R155H mutation in a pathologically proven case of ALS. VCP protein is essential for maturation of ubiquitin-containing autophagosomes, and mutant VCP toxicity is partially mediated through its effect on…

Adenosine TriphosphataseMaleCell Cycle ProteinsUBQLN2Cohort Studies0302 clinical medicineReference ValuesValosin Containing ProteinCell Cycle ProteinReference ValueAmyotrophic lateral sclerosisExome sequencingAdenosine TriphosphatasesGenetics0303 health sciencesGeneral NeuroscienceExonsMiddle AgedPedigree3. Good healthMultisystem proteinopathyFemaleSettore MED/26 - NeurologiaCase-Control StudieChromosomes Human Pair 9HumanFrontotemporal dementiaNeuroscience(all)Valosin-containing proteinExonBiologyProtein degradationTARDBPArticle03 medical and health sciencesmedicineHumansAged030304 developmental biologyAmyotrophic lateral sclerosis familial ALS exome sequencingNeuroscience (all)business.industryAmyotrophic Lateral Sclerosismedicine.diseaseAmino Acid SubstitutionCase-Control StudiesMutationbiology.proteinCohort Studiebusiness030217 neurology & neurosurgeryAmyotrophic Lateral SclerosiNeuron
researchProduct

A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy

2007

Mutations in the Angiogenin gene (ANG) linked to 14q11.2 have been recently discovered to be associated with Amyotrophic Lateral Sclerosis (ALS) in Irish and Scottish populations. In our study we investigated the role of ANG gene in ALS patients from southern Italy. We found a novel mutation in the signal peptide of the ANG gene in a sporadic patient with ALS (SALS). The molecular analysis of the ANG gene also demonstrated an allelic association with the rs11701 single nucleotide polymorphism (SNP) in familial ALS (FALS) but not in SALS patients. Our finding supports the evidence that the ANG gene is involved in ALS.

AdultGenetic MarkersMaleSignal peptideAngiogenin geneAngiogeninGenetic LinkageDNA Mutational AnalysisSingle-nucleotide polymorphismGene mutationBiologyPolymorphism Single NucleotidemedicineHumansSNPGenetic Predisposition to DiseaseGenetic TestingAlleleAmyotrophic lateral sclerosisGeneGenetics (clinical)AgedChromosomes Human Pair 14Motor NeuronsGeneticsAmyotrophic Lateral SclerosisChromosome MappingRibonuclease PancreaticMiddle Agedmedicine.diseaseAssociation studyAmino Acid SubstitutionItalyNeurologyCytoprotectionMutationNerve DegenerationPediatrics Perinatology and Child Healthcardiovascular systemCancer researchFemaleNeurology (clinical)ALShormones hormone substitutes and hormone antagonistsNeuromuscular Disorders
researchProduct

The Primitive Palmomental Reflex in Amyotrophic Lateral Sclerosis

2017

<b><i>Background and Purpose:</i></b> The palmomental reflex (PMR) is a primitive reflex that might be released due to inhibition in adulthood. It has been associated with several neurodegenerative conditions. The aim of the present study was to evaluate the frequency of PMR in amyotrophic lateral sclerosis (ALS). <b><i>Patients and Methods:</i></b> Non-demented ALS patients (<i>n</i> = 179) were recruited. Two groups of disease controls were enrolled: (a) non-demented patients with other neurological disorders (NC;<i> n</i> = 86, mean age 60 ± 14 years); (b) healthy subjects, healthy controls (HC; <i>n</i> …

AdultMale0301 basic medicinePrimitive reflexesmedicine.medical_specialtyGastroenterologyPalmomental reflex03 medical and health sciences0302 clinical medicineInternal medicinePrimitive reflexemedicineHumansPalmomental reflexAmyotrophic lateral sclerosisStrokeAmyotrophic lateral sclerosiAgedPyramidal tractsReflex Abnormalbusiness.industryAmyotrophic Lateral SclerosisMiddle Agedmedicine.disease030104 developmental biologymedicine.anatomical_structureIncreased riskNeurologyReflexFemalePyramidal tractNeurology (clinical)business030217 neurology & neurosurgeryThenar eminenceEuropean Neurology
researchProduct

Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis

2015

Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti-apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS). Methods: As a proof of principle, using a double-blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were e…

AdultMale0301 basic medicineamyotrophic lateral sclerosismedicine.medical_specialtyALS - TUDCA - clinical trialmedicine.drug_classPilot ProjectsAmyotrophic lateral sclerosis; Cholic acids; Tauroursodeoxycholic acid; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Drug Therapy Combination; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Riluzole; Taurochenodeoxycholic Acid; Outcome Assessment (Health Care); Neurology; Neurology (clinical)PlaceboNeuroprotectionGastroenterologyTaurochenodeoxycholic AcidOutcome Assessment (Health Care)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodDrug TherapyInternal medicinemedicineCholic acidHumansAmyotrophic lateral sclerosisAdverse effectAmyotrophic lateral sclerosiAgedtauroursodeoxycholic acidRiluzoleBile acidbusiness.industryTauroursodeoxycholic acidMiddle Agedmedicine.diseaseRiluzoleSurgerySettore MED/26 - NEUROLOGIANeuroprotective Agentscholic acids030104 developmental biologyNeurologychemistryTolerabilityCombinationFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugEuropean Journal of Neurology
researchProduct